ClinicalTrials.gg
RecruitingNCT07516288Updated Jul 2, 2026

Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy

A Phase 1 interventional study of FAP immunosuppressive CAR-DC in Dilated Cardiomyopathy (DCM) and Heart Failure, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Cardiomyopathy, Dilated · China.

Planned enrollment
12th of 12
5 · median 43
Started
2026
with 2 others
Phase 1
3 of 23
1 open now
Primary completion
2027-12
later than 7 of 13 live
Registered
20th of 23
by date
Lead sponsor
3 of 23
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 23 studies in Cardiomyopathy, Dilated with a site in China, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 7 of the 13 other live ones, and was the 20th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

13 of the 23 studies in Cardiomyopathy, Dilated with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy.

Previous clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.

Read the detailed description

Heart failure is a life-threatening syndrome with high morbidity and mortality. Dilated cardiomyopathy (DCM) is a major cause of end-stage heart failure, and currently available treatments for advanced DCM remain limited.

Immune activation and myocardial fibrosis play key roles in the progression of heart failure. Targeting cardiac fibrosis through immune modulation has emerged as a potential therapeutic strategy. Our research group has developed a novel immunosuppressive chimeric antigen receptor-modified dendritic cell (CAR-DC) therapy targeting fibroblast activation protein (FAP), designed to reduce cardiac fibrosis and improve cardiac function.

Preclinical studies demonstrated that FAP-targeted immunosuppressive CAR-DC (iCDC) therapy significantly improved cardiac function and survival in animal models of heart failure, with a favorable safety profile. Based on these findings, an exploratory clinical study of single-dose iCDC infusion in patients with end-stage DCM has been conducted, and preliminary follow-up results up to three months have shown good safety and potential clinical benefit.

However, in clinical practice, patients with end-stage DCM may experience recurrent deterioration of cardiac function due to infections or other triggers. Whether a second administration of iCDC can restore or further improve cardiac function remains unknown.

Therefore, this study aims to evaluate the safety and preliminary efficacy of a second infusion of FAP-targeted immunosuppressive CAR-DC in patients with end-stage dilated cardiomyopathy who experience worsening heart function after initial treatment.

03

Conditions studied

  • Dilated Cardiomyopathy (DCM)
  • Heart Failure

Keywords

  • end-stage dilated cardiomyopathy
  • FAP immunosuppressive CAR-DC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years and ≤75 years of age, with a confirmed diagnosis of dilated cardiomyopathy.
  • Patients who previously received a single infusion of CAR-DC (iCDC) therapy and, at 6 months after the first treatment, failed to maintain improvement in cardiac function, with cardiac function declining to baseline levels prior to treatment. These patients should have persistent heart failure symptoms that cannot be adequately improved, with (LVEF) \<35%, (NYHA) functional class III-IV, and INTERMACS profile 3-6.
  • Able to verbally confirm understanding of the risks, benefits, and alternative treatment options of the second administration of iCDC therapy, and willing to participate in the study. The participant or his/her legal representative must provide written prior to enrollment.
  • Hematocrit >30%, lymphocyte count >0.5 × 10⁹/L, and count >60 × 10⁹/L.

Exclusion criteria

Exclusion Criteria:

  • Severe renal failure or requirement for renal dialysis, or serum creatinine >2.5 mg/dL.
  • (AST) or alanine aminotransferase (ALT) levels greater than 5.0 times the (ULN), or total >3 mg/dL.
  • Presence of active infections at screening, including: Active infection with hepatitis B virus DNA >1000 copies/mL by PCR testing; virus infection; Syphilis; (HIV) infection; Uncontrolled systemic fungal, bacterial, viral, or other pathogenic infections.
  • Severe hemodynamic instability (e.g., shock).
  • Known to the product or study-related procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    dilated cardiomyopathy

    All participants will receive a second infusion of CAR-DC at the predetermined safe and effective dose of 4×10⁵ cells/kg, administered intravenously.

    Biological: FAP immunosuppressive CAR-DC

Interventions

  • BiologicalFAP immunosuppressive CAR-DC

    Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with Dose-limiting toxicity (DLT)

    The proportion of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: in 14 days after injection

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of iCDC treatment-emergent adverse events

    Time frame: in 14 days after injection

Secondary outcomes

  1. Left ventricular ejection fraction (LVEF)

    The difference of LVEF from baseline. LVEF will be assessed by echocardiography.

    Time frame: 1, 3, 6 months after injection

  2. Left ventricular ejection fraction (LVEF)

    The difference of LVEF from baseline. LVEF will be assessed by Cardiac Magnetic Resonance (CMR).

    Time frame: 6 months after injection

  3. Enhanced volume (volume%)

    The difference of Enhanced volume (volume%) from baseline. Enhanced volume will be assessed by CMR.

    Time frame: 6 months after injection

  4. INTERMACS Profile

    Profile 1. Critical cardiogenic shock; Profile 2. Progressive decline on inotropic support; Profile 3. Stable but inotrope dependent; Profile 4. Resting symptoms home on oral therapy; Profile 5. Exertion Intolerant; Profile 6. Exertion Limited; Profile 7. Advanced NYHA Class III symptoms

    Time frame: 1, 3, 6 months after injection

  5. Left ventricular internal diameter end systole (LVIDs)

    The difference of LVIDs from baseline. LVIDs will be assessed by echocardiography.

    Time frame: 1, 3, 6 months after injection

  6. Left ventricular internal diameter end diastole (LVIDd)

    The difference of LVIDd from baseline. LVIDd will be assessed by echocardiography.

    Time frame: 1, 3, 6 months after injection

  7. Left ventricular end-systolic volume (LVESV)

    The difference of LVESV from baseline. LVESV will be assessed by CMR.

    Time frame: 6 months after injection

  8. Left ventricular end-diastolic volume (LVEDV)

    The difference of LVEDV from baseline. LVEDV will be assessed by CMR.

    Time frame: 6 months after injection

  9. NT-proBNP

    Analysis of differences of NT-proBNP serum level from baseline.

    Time frame: 1, 3, 6 months after injection

  10. 6 minutes walk test (6MWT)

    The difference of 6MWT from baseline.

    Time frame: 1, 3, 6 months after injection

  11. Change in New York Heart Association (NYHA) Functional Classification

    Assessment of heart failure symptom severity using the New York Heart Association (NYHA) functional classification. NYHA class ranges from I to IV, with higher classes indicating worse functional status.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  12. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score

    Assessment of heart failure-related health status using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ score ranges from 0 to 100, with higher scores indicating better health status and quality of life.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  13. Incidence of major adverse cardiovascular events (MACE)

    Incidence of Cardiac death, readmission due to heart failure.

    Time frame: 1, 3, 6 months after injection

  14. incidence of adverse events

    Incidence of adverse events of heart, nerve system, mental system, digestive system and immune system.

    Time frame: 6 months after injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 7, 2026
StartActual
May 11, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516288
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 11, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Jiamin Li, MD
Contact
21818216@zju.edu.cn
86-18868112006
Xinyang Hu, PhD
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion